Clinical Trial

CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to study how CMVIG interacts with the body and to see if it might work to prevent kidney transplant patients from becoming infected with CMV.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-24; most recent amendment 2025-10-29.
Status change: Not Yet Recruiting → Recruiting 2025-10-29
Trial Details
NCT Number NCT07096453
Lead Sponsor University of Minnesota
Conditions Kidney Transplant; Complications, CMV
Enrollment 30 participants
Start Date 2025-10-02
Primary Completion 2027-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2025-10-31